Processa Pharmaceuticals Announces Relocation of 2025 Stockholder Meeting to Pasadena, CA.

Processa Pharmaceuticals has relocated its 2025 stockholder meeting from Vero Beach, FL to Pasadena, CA. The company's board of directors made the logistical adjustment. The most recent analyst rating on PCSA stock is a Buy with a $2.00 price target. Processa Pharmaceuticals is facing significant financial challenges with no revenue generation and ongoing losses, and technical indicators point to bearish momentum.

Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) has announced a change in the location of its 2025 Special Meeting of Stockholders. Originally scheduled to be held at 601 21st Street, Suite 300, Vero Beach, Florida, the meeting will now take place at 594 East Colorado Blvd., Suite 200, Pasadena, California [1]. The board of directors made this logistical adjustment on Monday, with the date and time of the meeting remaining unchanged from the previously disclosed proxy statement filed on August 13, 2025 [1].

The company, incorporated in Delaware and listed on the Nasdaq Capital Market, has been facing significant financial challenges, including no revenue generation and ongoing losses. Despite these challenges, analysts remain optimistic. H.C. Wainwright has reiterated a Buy rating on PCSA stock, setting a price target of $2.00 [1]. The firm highlights the ongoing clinical development of Processa’s lead oncology asset, NGC-Cap, and plans for a new Phase 3 study for PCS499 in rare kidney diseases [1]. Processa is also exploring cryptocurrency treasury strategies to diversify its capital base, aiming to enhance financial flexibility and support clinical development programs [1].

Technical indicators suggest bearish momentum for PCSA stock, but the company's strategic investments and clinical pipeline may provide a turnaround. The upcoming Annual Shareholder Meeting is set for July 18 in Hanover, Maryland, following the successful achievement of a quorum [1].

References:
[1] https://www.investing.com/news/sec-filings/processa-pharmaceuticals-changes-location-of-2025-special-stockholders-meeting-93CH-4209898